康为世纪拟收购昊为泰49%股权，实现全资控股

Core Viewpoint - 康为世纪 plans to acquire the remaining 49% stake in its subsidiary, 上海昊为泰生物科技有限公司, for 17.885 million yuan, making it a wholly-owned subsidiary, which aims to enhance management control and improve overall profitability and competitiveness [1] Group 1: Acquisition Details - 康为世纪 currently holds a 51% stake in 昊为泰 and intends to purchase the remaining 49% from 上海天昊生物科技有限公司 [1] - The acquisition price is set at 17.885 million yuan [1] Group 2: Business Operations of 昊为泰 - 昊为泰's primary revenue comes from technology service income, including various testing services such as microbiome testing, multi-omics integration analysis, third-generation sequencing, single-cell sequencing, metabolomics, proteomics testing, and bioinformatics analysis [1] Group 3: Strategic Rationale - The acquisition aligns with 康为世纪's future strategic development plans and operational needs, aiming to strengthen control over 昊为泰 and enhance decision-making efficiency [1] - This move is expected to bolster the company's overall profitability and competitive edge in the market [1]